Biopharmaceutical research, precision medicine, and therapeutic development by Spyre Therapeutics
Paul Fehlner joins Spyre Therapeutics, Inc. as Chief IP Counsel with science and law expertise
Spyre Therapeutics, Inc. has announced the appointment of Paul Fehlner as Chief IP Counsel, bringing more than thirty years of experience at the intersection of science and law. Fehlner is ...
Spyre Therapeutics, Inc. secures spot on 2026 IncBestWorkplaces list for dynamic team culture
Spyre Therapeutics, Inc. has been recognized as one of the 2026 IncBestWorkplaces, underscoring its commitment to fostering a dynamic and award-winning workplace culture. The company attributes ...
Spyre Therapeutics, Inc. advances new therapies for ulcerative colitis and Crohns disease
Spyre Therapeutics, Inc. marked World IBD Day by announcing its work on next-generation combination treatments for people living with inflammatory bowel diseases, including ulcerative colitis and ...
Spyre Therapeutics, Inc. raises 463.5 million dollars in public offering as underwriters fully exercise option
Spyre Therapeutics, Inc. announced the completion of its public offering, raising approximately 463.5 million dollars in gross proceeds. The capital raise includes the full exercise of the ...
Spyre Therapeutics, Inc. advances SPY001 into next trial phase after meeting primary endpoint
Spyre Therapeutics, Inc. announced positive results from the Part A segment of its Phase 2 clinical trial of SPY001 in patients with ulcerative colitis. The company reported that SPY001 reached ...
Spyre Therapeutics, Inc. team assembles 1,500 kits for students during annual gathering
Spyre Therapeutics, Inc. recently brought its team together for an annual in-person event, where employees assembled 1,500 kits for local students as part of the company's Women's History Month ...
RA sub-study patient enrollment ends in Phase 2 SKYWAY trial as Spyre Therapeutics, Inc. eyes data release
Spyre Therapeutics, Inc. has finished recruiting patients for the rheumatoid arthritis (RA) sub-study in its Phase 2 SKYWAY clinical trial. The company expects to announce topline results from ...
Spyre Therapeutics, Inc. targets breakthrough in inflammatory bowel disease with combination therapies
Spyre Therapeutics, Inc. is intensifying efforts to transform the treatment landscape for inflammatory bowel disease, as CEO Cameron Turtle collaborates with leading gastroenterologists to ...
